HYALURONIDASE-FACILITATED SUBCUTANEOUS IMMUNOGLOBULIN 10% FOR CIDP: FINAL RESULTS FROM A LONG-TERM SAFETY AND TOLERABILITY STUDY

被引：0
|
作者：
Hadden, Robert [1 ,2 ]
Andersen, Henning [3 ]
Bril, Vera [4 ]
Basta, Ivana [5 ]
Rejdak, Konrad [6 ]
Duff, Kim [7 ]
Greco, Erin [7 ]
Hasan, Shabbir [7 ]
Anderson-Smits, Colin [7 ]
Ay, Hakan [7 ]
机构：
[1] Kings Coll Hosp London, Dept Neurol, London, England
[2] Kings Coll London, Inst Psychiat Psychol & Neurosci, Dept Basic & Clin Neurosci, London, England
[3] Aarhus Univ, Aarhus, Denmark
[4] Univ Toronto, Univ Hlth Network, Ellen & Martin Prosserman Ctr Neuromuscular Dis, Toronto, ON, Canada
[5] Univ Belgrade, Univ Clin Ctr Serbia, Neurol Clin, Fac Med, Belgrade, Serbia
[6] Med Univ Lublin, Dept Neurol, Lublin, Poland
[7] Takeda Dev Ctr Amer Inc, Cambridge, MA USA
来源：
JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM | 2024年 / 29卷
关键词：
Chronic inflammatory demyelinating polyradiculoneuropathy; facilitated subcutaneous immunoglobulin; safety and tolerability efficacy; ADVANCE-CIDP; 3;
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P 189
引用
收藏
页码：S78 / S79
页数：2
相关论文
共 50 条
  • [1] Facilitated subcutaneous immunoglobulin 10% for CIDP: interim results from a long-term safety and tolerability study
    Hadden, R.
    Andersen, H.
    Bril, V.
    Basta, I.
    Rejdak, K.
    Djordjevic, G.
    Greco, E.
    Hasan, S.
    French, J.
    Yel, L.
    Ay, H.
    EUROPEAN JOURNAL OF NEUROLOGY, 2023, 30 : 286 - 286
  • [2] Long-term safety and tolerability of hyaluronidase-facilitated subcutaneous immunoglobulin 10% as maintenance therapy for chronic inflammatory demyelinating polyradiculoneuropathy: Results from the ADVANCE-CIDP 3 trial
    Hadden, Robert D. M.
    Andersen, Henning
    Bril, Vera
    Basta, Ivana
    Rejdak, Konrad
    Duff, Kim
    Greco, Erin
    Hasan, Shabbir
    Anderson-Smits, Colin
    Ay, Hakan
    JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM, 2024, 29 (04) : 441 - 452
  • [3] Long-term safety of hyaluronidase-facilitated subcutaneous immunoglobulin 10%: a European post-authorization study
    Ellerbroek, Pauline M.
    Hanitsch, Leif G.
    Witte, Torsten
    Lougaris, Vassilios
    van Hagen, P. Martin
    Paassen, Pieter van
    Chen, Jie
    Fielhauer, Katharina
    McCoy, Barbara
    Nagy, Andras
    Yel, Leman
    IMMUNOTHERAPY, 2024, 16 (10) : 679 - 691
  • [4] Long-Term Tolerability, Safety, and Efficacy of Recombinant Human Hyaluronidase-Facilitated Subcutaneous Infusion of Human Immunoglobulin for Primary Immunodeficiency
    Wasserman, Richard L.
    Melamed, Isaac
    Stein, Mark R.
    Engl, Werner
    Sharkhawy, Marlies
    Leibl, Heinz
    Puck, Jennifer
    Rubinstein, Arye
    Kobrynski, Lisa
    Gupta, Sudhir
    Grant, Andrew J.
    Ratnayake, Anoshie
    Richmond, Wendell G.
    Church, Joseph
    Yel, Leman
    Gelmont, David
    JOURNAL OF CLINICAL IMMUNOLOGY, 2016, 36 (06) : 571 - 582
  • [5] Long-Term Tolerability, Safety, and Efficacy of Recombinant Human Hyaluronidase-Facilitated Subcutaneous Infusion of Human Immunoglobulin for Primary Immunodeficiency
    Richard L. Wasserman
    Isaac Melamed
    Mark R. Stein
    Werner Engl
    Marlies Sharkhawy
    Heinz Leibl
    Jennifer Puck
    Arye Rubinstein
    Lisa Kobrynski
    Sudhir Gupta
    Andrew J. Grant
    Anoshie Ratnayake
    Wendell G. Richmond
    Joseph Church
    Leman Yel
    David Gelmont
    Journal of Clinical Immunology, 2016, 36 : 571 - 582
  • [6] Mechanism of action and long-term tolerability of hyaluronidase-facilitated subcutaneous immunoglobulin (IGHy) in primary immunodeficiency diseases
    Sehinovych, Ihor
    Melamed, Isaac
    Gupta, Sudhir
    Sehinovych, Ihor
    Hermann, Corinna
    Engl, Werner
    McCoy, Barbara
    Leibl, Heinz
    Yel, Leman
    JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM, 2018, 23 (04) : 288 - 289
  • [7] Interim analysis of a postauthorization safety study on long-term safety of hyaluronidase-facilitated subcutaneous immunoglobulin 10% in primary immunodeficiency disease in Europe
    Ellerbroek, P. M.
    van Paassen, P.
    Hanitsch, L.
    Plebani, A.
    Schmidt, R. E.
    van Hagen, P. M.
    Wang, P.
    Fielhauer, K.
    Leibl, H.
    Yel, L.
    SWISS MEDICAL WEEKLY, 2019, : 17S - 17S
  • [8] POPULATION PHARMACOKINETIC SIMULATIONS IN CIDP AND MMN: HYALURONIDASE-FACILITATED SUBCUTANEOUS IMMUNOGLOBULIN AND INTRAVENOUS IMMUNOGLOBULIN G 10%
    Freedman, Immanuel
    Roepcke, Stefan
    Li, Zhaoyang
    JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM, 2024, 29 : S91 - S92
  • [9] EUROPEAN POSTAUTHORIZATION SAFETY STUDY ON LONG-TERM HYALURONIDASE-FACILITATED SUBCUTANEOUS IMMUNOGLOBULIN IN PRIMARY IMMUNODEFICIENCY DISEASES: INTERIM ANALYSIS
    Ellerbroek, Pauline M.
    van Paassen, Pieter
    Hanitsch, Leif
    Plebani, Alessandro
    Schmidt, Reinhold E.
    van Hagen, P. Martin
    Wang, Ping
    Fielhauer, Katharina
    Leibl, Heinz
    Chavan, Shailesh
    Yel, Leman
    MUSCLE & NERVE, 2020, 62 : S67 - S68
  • [10] PATIENT-REPORTED OUTCOMES WITH HYALURONIDASE-FACILITATED SUBCUTANEOUS IMMUNOGLOBULIN 10% AND INTRAVENOUS IMMUNOGLOBULIN 10%: THE ADVANCE-CIDP 1 STUDY
    Anderson-Smits, Colin
    Ay, Hakan
    Greco, Erin
    Hasan, Shabbir
    JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM, 2024, 29 : S81 - S81
12345